Begin first patient dosing for AMT-260
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Oct 2023
- Due
- 31 Mar 2024
- Delivered
- November 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“first patient dosing occurring in the first quarter of 2024.”
What we found
Evidence strength A What the grades mean
The company committed to dosing the first patient in the first quarter of 2024, but filings confirm the first patient was not dosed until November 2024.
-
A uniQure N.V. 10-K filed 2025-02-27
“In December 2024, we made a payment of EUR 30.0 million ($31.5 million) to the former shareholders of uniQure France SAS following the dosing of the first patient in Phase I/II clinical trial for AMT-260.” ✓ confirmed on the page
-
A uniQure N.V. 10-Q filed 2025-05-09
“In November 2024 we announced that the first patient had been dosed in GenTLE.” ✓ confirmed on the page
Market reaction: the shares moved +0.7% against the S&P 500 over the three sessions around the disclosure (8 May 2025 to 13 May 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- AMT-260 first patient dosing
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-QURE-001853 · Corrections policy